Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3474066 | 0.85 | KMT2A (0.52) | SMN1; SMN2HTTMAPTMEN1KMT2A | |
| SCHEMBL13202429 | 0.78 | RXFP1 (0.62) | SMN1; SMN2HTTLMNARXFP1MAPT | |
| SCHEMBL3473620 | 0.77 | PGR (0.48) | SMN1; SMN2HTTLMNAMAPTMEN1 | |
| SCHEMBL13202406 | 0.76 | RXFP1 (0.62) | SMN1; SMN2HTTLMNARXFP1MEN1 | |
| SCHEMBL3473744 | 0.74 | BCL2L1 (0.60) | SMN1; SMN2HTTRXFP1MAPTMEN1 | |
| SCHEMBL13315734 | 0.73 | RXFP1 (0.64) | SMN1; SMN2HTTLMNARXFP1RAB9A | |
| SCHEMBL5491795 | 0.72 | RXFP1 (0.88) | RXFP1MAPTKMT2AKCNK3KCNK9 | |
| SCHEMBL19425477 | 0.71 | MEN1 (0.56) | SMN1; SMN2HTTRXFP1MAPTMEN1 | |
| SCHEMBL13561150 | 0.71 | MAPT (0.68) | SMN1; SMN2HTTLMNARXFP1MAPT | |
| SCHEMBL15528909 | 0.70 | RXFP1 (1.00) | RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418942-B1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8436207-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2418942-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | Sanford-Burnham Medical Research Institute (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120943-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | HAX1, BAX, APOL1 | SMN1; SMN2 2591/4885HTT 1095/4885LMNA 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.